Research programme: antibacterials - Cumbre Pharmaceuticals

Drug Profile

Research programme: antibacterials - Cumbre Pharmaceuticals

Alternative Names: Anti-tuberculosis agents research programme - Cumbre Pharmaceuticals; Antibacterials research programme - Cumbre Pharmaceuticals; CBR 703 series - Cumbre Pharmaceuticals; Research programme: RNA polymerase inhibitors - Cumbre Pharmaceuticals; RNA polymerase inhibitors research programme - Cumbre Pharmaceuticals

Latest Information Update: 29 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cumbre Pharmaceuticals
  • Class Amidines; Hydroxylamines
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Protein synthesis inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Tuberculosis

Most Recent Events

  • 23 Oct 2003 Preclinical trials in Bacterial infections in USA (unspecified route)
  • 11 Mar 1999 Preclinical development for Bacterial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top